QQ客服 官方微博 反馈留言

浏览/检索结果: 共4条，第1-4条 帮助 限定条件 内容类型：会议论文     已选(0)清除 条数/页：5101520253035404550556065707580859095100   排序方式：请选择作者升序作者降序题名升序题名降序发表日期升序发表日期降序提交时间升序提交时间降序 SECUKINUMAB PROVIDES RAPID AND SIGNIFICANT IMPROVEMENT IN THE SIGNS AND SYMPTOMS OF ANKYLOSING SPONDYLITIS: PRIMARY (16-WEEK) RESULTS FROM A PHASE 3 CHINA-CENTRIC STUDY, MEASURE 5 会议论文 作者:  Huang, Feng;  Sun, Fei;  Wan, Weiguo;  Wu, Lijun;  Dong, Lingli 收藏  |  浏览/下载：29/0  |  提交时间：2019/12/05 First-line afatinib (A) vs gefitinib (G) for patients (pts) with EGFR mutation positive (EGFRm plus ) NSCLC (LUX-Lung 7): Patient-reported outcomes (PROs) and impact of dose modifications on efficacy and adverse events (AEs). 会议论文 JOURNAL OF CLINICAL ONCOLOGY, 2016-05-20 作者:  Hirsh, Vera;  Yang, James Chih-Hsin;  Tan, Eng-Huat;  O'Byrne, Ken;  Zhang, Li 收藏  |  浏览/下载：7/0  |  提交时间：2020/01/04 Results of a global phase II study with crizotinib in advanced ALK-positive non-small cell lung cancer (NSCLC). 会议论文 JOURNAL OF CLINICAL ONCOLOGY, 2012-05-20 作者:  Kim, Dong-Wan;  Ahn, Myung-Ju;  Shi, Yuankai;  De Pas, Tommaso Martino;  Yang, Pan-Chyr 收藏  |  浏览/下载：1/0  |  提交时间：2020/01/13 Visual effects in anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC) patients treated with crizotinib. 会议论文 JOURNAL OF CLINICAL ONCOLOGY, 2012-05-20 作者:  Salgia, Ravi;  Solomon, Benjamin J.;  Shaw, Alice Tsang;  Camidge, D. Ross;  Evans, Tracey L. 收藏  |  浏览/下载：1/0  |  提交时间：2020/01/13